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Abstract: The critical initial steps in insulin action include phosphorylation of adapter 
proteins and activation of phosphatidylinositol 3-kinase (PI3K). One of important 
components in this process is a protein called Akt/protein kinase B (PKB). The work of 
numerous different researchers indicates a role of PKB in regulating insulin-stimulated 
glucose uptake. The crucial role of lipid second messengers in PKB activation has been 
dissected through the use of the PI3K-specific inhibitors wortmannin and LY294002. 
Receptor-activated PI3K synthesizes the lipid second messenger PtdIns[3,4,5]-
trisphosphate, leading to the recruitment of PKB to the membrane. Membrane attachment 
of PKB is mediated by its pleckstrin homology domain binding to PtdIns[3,4,5]-
trisphosphate or PtdIns[3,4]-bisphosphate with high affinity. Activation of PKB alpha is 
then achieved at the plasma membrane by phosphorylation of Thr308 in the activation-loop 
of the kinase domain and Ser473 in the carboxy-terminal regulatory region, respectively. 3-
Phosphoinositide-dependent protein kinase-1 (PDK1) is responsible for T308 
phosphorylation. The usage of specific inhibitors and natural compound has significantly 
contributed to investigate the molecular mechanism of PI3K/PDK1/PKB signaling 
pathway, leading to the putative therapeutics benefits of patients. This review focuses on 
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the contribution of natural inhibitor or compound in our understanding of the mechanism 
by which insulin induces, especially in PI3K/ PDK1/PKB signaling. 
Keywords: Diabetes mellitus; phosphatidylinositol 3-kinase; 3-Phosphoinositide-dependent 
protein kinase-1; protein kinase B; natural inhibitors. 
 
1. Introduction 
The discovery, production, and clinical use of insulin in the 1920s greatly prolonged the life 
expectancy of patients with insulin-dependent diabetes mellitus [1]. It is now established that diabetes 
mellitus is the most common cause of end-stage renal failure, blindness, and lower limb amputations in 
adults, and is a major risk factor for cardiovascular disease and stroke [2]. Today, diabetes is the most 
common metabolic disease in the world. Almost every day, 1,700 new cases of diabetes are diagnosed 
in the United States [3]. Normal glucose homeostasis requires the finely tuned orchestration of insulin 
secretion by pancreatic β cells in response to subtle changes in blood glucose levels, delicately 
balanced with secretion of counter-regulatory hormones such as glucagon. The importance of insulin 
in glucose homeostasis is emphasized in metabolic malfunctions in which insulin action is defective 
[4]. Autophosphorylation of the insulin receptor by insulin results in the recruitment and activation of 
intracellular downstream signaling molecules and leads to glucose uptake and various other biological 
effects [5]. A lack of insulin or insulin resistance, or defects in the insulin signaling pathways are the 
cause of metabolic diseases such as diabetes mellitus, which is characterized by hyperglycemia [6]. 
Therefore, to make better treatment of such relevant diseases, it is absolutely necessary for us to 
understand as to how intracellular signaling molecules can be activated by insulin action. Some natural 
products indeed greatly helped us to understand insulin-induced molecular events. In this review, we 
focused on PI3K/PDK1/PKB pathway, a major signaling part, triggered by insulin and its 
understanding by naturally occurring inhibitors derived from microorganisms. 
 
2. Natural inhibitors targeting PI3K/PDK1/PKB pathway in insulin-mediated signaling events     
At present, the treatment of diabetes mainly involves a sustained reduction in hyperglycemia by the 
use of biguanides, thiazolidinediones, sulphonylureas, D-phenylalanine derivatives, meglitinides and 
α-glucosidase inhibitors in addition to insulin. However, due to unwanted side effects the efficacies of 
these compounds are debatable and there is a demand for new compounds for the treatment of diabetes 
[7]. Natural products have been suggested as a rich, as yet unexplored source of potentially useful 
antidiabetic drugs. These compounds, produced by plant, bacteria and fungi, can be toxic to other 
organisms and have a variety of physiological effects in animals. Many pharmaceutical agents have 
been discovered by screening natural products from a wide range of microorganisms and event plants. 
For example, rapamycin (sirolimus) was originally discovered at Wyeth-Ayerst Pharmaceuticals in a 
screen for antifungal agents and later found to have potent immunosuppressive activity [8]. In addition, 
the natural products rapamycin, wortmannin, geldanamycin and okadaic acid have been found to 
possess various pharmacological effects such as immunosuppressive and anti-proliferative actions [9; Int. J. Mol. Sci. 2008, 9  
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10]. Through numerous molecular studies, it has been demonstrated that their molecular targets are 
interestingly found at insulin signaling cascades.   
 
2.1. Wortmannin: An inhibitor of PI-3-kinase family members 
Wortmannin is a hydrophobic estrogen-related fungal metabolite (Figure 1A) from the fungus 
Talaromyces wortmanni [11]. The in vivo anti-inflammatory and immunosuppressive effects shown by 
wortmannin first suggested that it was a potent inhibitor of signal transduction pathways [11]. 
Wortmannin blocks cellular responses emanating from stimulation of G-protein-coupled receptors. For 
example, wortmannin inhibits stimulation of neutrophils  [12], histamine secretion by basophilic 
leukemia cells [13] and nitric-oxide production in macrophages [14].  
 
Figure 1. Molecular structures of natural products that inhibit insulin signaling. 
 
 
In mammalian cells, several lines of evidence indicate that the growth-factor-activated PI-3 kinase 
(PI3K) is potently inhibited by wortmannin, which was originally isolated from soil bacteria [15]. 
PI3K was originally identified as the protein responsible for the phosphorylation of the D-3 position on 
the inositol head group of phosphoinositides (Figure 2) [16]. There is growing evidence to suggest that 
insulin stimulation of PI3K is essential for insulin’s regulation of metabolism. This conclusion is 
largely based on studies using two structurally independent PI3K inhibitors, wortmannin and 
LY294002. These inhibitors block insulin stimulation of a number of metabolically important Int. J. Mol. Sci. 2008, 9  
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responses including the antilipolytic effect [17], activation of acetyl CoA carboxylase [18] and 
induction of membrane ruffling [19]. Importantly for insulin’s regulation of glucose metabolism it has 
been found that wortmannin blocks activation of glycogen synthase [20]. Wortmannin also blocks 
insulin stimulation of signaling intermediates such as the 70 kDa ribosomal protein S6-kinase 
(p70S6K) [21], Protein kinase B (PKB) [22] and in parallel activates glycogen synthase kinase-3 
(GSK-3) [23]. These studies place PKB upstream of GSK-3 activation and also upstream of p70S6K 
activation (Figure 2). This is important as both GSK-3 and p70S6K have been implicated as elements 
of insulin signaling pathways leading to glycogen synthase activation. Therefore these studies begin to 
suggest the layout of signaling pathways linking the insulin receptor with regulation of glycogen 
synthase. 
Wortmannin also inhibits the antigen-dependent stimulation of PI3K activity in basophils [24] as 
well as stimulated PtdIns[3,4,5]-trisphosphate production in neutrophils [25], consistent with a block in 
PtdIns[4,5]-bisphosphate phosphorylation by PI3K; purified p110–p85 PI3K is potently inhibited by 
wortmannin  in vitro [26]. Furthermore, studies with anti-wortmannin antibodies and site-directed 
mutagenesis reveal that wortmannin forms a covalent complex with an active-site residue of bovine 
PI3K, lysine 802 of the 110 kDa catalytic subunit [27]. This active-site lysine residue is essential for 
PI3K activity and is well conserved throughout all members of the PI3K-related protein family.   
Although wortmannin potently inhibits the PI3-kinase with a 50% inhibitory concentration (IC50) of 
5 nM, more recent studies have shown that it also inhibits PI4-kinases. A wortmannin-sensitive 
membrane-associated PI4-kinase was identified and cloned in mammalian cells [28]. 
Demethoxyviridin, a structural analog of wortmannin, inhibits an unidentified membrane-associated 
PI4-kinase from the fission yeast Schizosaccharomyces pombe (IC50 = 100 nM) [29]. Interestingly, 
wortmannin is also toxic to the budding yeast S. cerevisiae. However, although wortmannin can inhibit 
the yeast PI3-kinase VPS34 in vitro at concentrations higher (IC50 = 3 μM) than those required to 
inhibit the mammalian PI3-kinase [30], mutant yeast cells lacking VPS34 are viable and remain 
wortmannin sensitive [31]. This result suggests that wortmannin toxicity in yeast is mediated via 
another target. These observations led to the identification of a wortmannin target in yeast as the PI4-
kinase STT4 [31]. Thus, overexpression of STT4 in yeast rescues cells from wortmannin toxicity. 
Moreover, STT4 PI4-kinase activity in vitro is sensitive to 10 nM wortmannin. The inhibitory activity 
of wortmannin is not restricted to PI3- and PI4-kinases, and at higher concentrations wortmannin also 
inhibits several members of a novel family of PI-related protein kinases. These wortmannin-sensitive 
enzymes include the mammalian target of rapamycin mTOR (IC50 = ~200 nM) [32] and yeast TOR1 
(IC50 = ~100 to 200 nM) [33], and also DNA damage control proteins including the human DNA-
dependent protein kinase (DNA-PK) (IC50 = 16 nM]) [34], the ataxia-telangiectaxia (AT) mutated 
(ATM) protein (IC50 = 150 nM), and the ATM and Rad3-related protein ATR (IC50 = 1.8 μM) [34, 35]. 
 
2.2. Geldanamycin: An inhibitor of Hsp90 and of Hsp90-dependent-signalling components 
Geldanamycin is a benzoquinone ansamycin (Figure 1C) natural-fermentation product that was 
originally thought to be a direct tyrosine-protein-kinase inhibitor. However, subsequent studies 
revealed that geldanamycin and two other structurally related analogues (herbimycin and macbecin) 
bind to and inhibit the functional role of 90 kDa heat-shock protein (Hsp90) instead [36]. Together Int. J. Mol. Sci. 2008, 9  
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with Hsp70 and a variety of other associated chaperones, including p60, p23, and immunophilins 
(cyclophilin 40 and FKBP52 or FKBP54), Hsp90 was highly conserved and played an important role 
in refolding certain denatured proteins under stress conditions. Unlike the more general Hsp70 and 
Hsp60 chaperones, Hsp90 appeared to have substrate-specific folding activity. Hsp90 has an additional 
role in the conformational regulation of certain signal transduction molecules. These include 
oncogenic kinases (e.g. v-Src and PKB) and a variety of members of the steroid-receptor family. 
Geldanamycin thus interferes with the activity of oncogenic kinases and steroid receptors by targeting 
their unique Hsp90-dependent function. Hsp90 functions as part of a multi-chaperone complex, 
involving the dynamic association with various accessory co-chaperones and client proteins [37]. 
Binding and hydrolysis of ATP are critical for the operation of a chaperone 'cycle', which involves a 
complex series of loading and unloading events that are essential for client protein stabilization and 
function. The ATP binding state of Hsp90 determines combinations of co-chaperones to bind at 
particular stages of the chaperone-client protein cycle. In particular, formation of a ‘mature’ Hsp90 
complex is required for client protein function and stability in an ATP-dependent manner. 
Geldanamycin docks in the ATP binding site located in the activity [38]. Consequently, the formation 
of mature Hsp90 complex and intrinsic ATPase activity cannot be occurred.   
Recently, the components of PI3K signaling pathway, such as PKB [39] and 3-Phosphoinositide-
dependent protein kinase-1 (PDK1) [40] are also suggested to be a client protein for Hsp90 in HEK 
293 cell and endothelial cells (Figure 2). It has been shown that Hsp90 can directly bind and stabilize 
PKB activity by preventing PP2A-mediated dephosphorylation [39]. Hsp90 can also recruit PKB to 
the eNOS complex during NO-dependent angiogenic processes [41]. Furthermore, it has also been 
suggested that Hsp90 acts on PDK1 in a similar manner to PKB [39, 40]. However, the mode of 
Hsp90’s action on PKB and PDK1 is somewhat different. Hsp90 inhibitors did not inhibit PKB-Hsp90 
binding or PKB activity itself [39; 42], whereas Hsp90 inhibitors are able to suppress PDK1-Hsp90 
complex formation, leading to PDK1 destabilization without directly inhibiting PDK1 activity [K, 
Yang and J, Park - unpublished data, [43]. The progress of geldanamycin into the clinic was stopped 
due to instability and the unacceptable hepatotoxicity seen at therapeutic doses during preclinical in 
vivo studies [44]. Further analogues were developed for clinical use, which included 17-AAG [45]. 
Once insulin binds to insulin receptor, the receptor gets dimerized and trans-phosphorylated in 
several tyrosine residues of the intracellular domain. This phospho-tyrosine acts as a docking site for 
insulin receptor substrate-1 (IRS1). IRS1 also is phosphorylated and recruits to the PI3K. The activated 
PI3K generates PtdIns[3,4,5]P3 from PtdIns[4,5]P2 on the plasma membrane. PKB and PDK1 then are 
recruited to plasma membrane wherein PDK1 activates PKB as well as p70S6K. Wortmannin inhibits 
the activity of PI3K which produces the PtdIns[3,4,5]-trisphosphate, PIP3, while okadaic acid blocks 
the activity of PP2A which is key serine/threonine phosphatase. Recently, it has been reported that 
Hsp90 is involved in PDK1 activation. Geldanamycin is also known to regulate the interaction 
between Hsp90 and PDK1 but not PKB in this process, although long exposure of this compound 
lowered PKB activity in the cells. Independently, FKBP12–rapamycin complex inhibits mTOR, 
leading to the inhibition of S6K. 
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Figure 2. Inhibition of each signaling molecules by natural products in insulin signaling. 
 
 
2.3. Okadaic acid : An inhibitor of serine/threonine protein phosphatase 
Okadaic acid is a marine natural toxin product (Figure 1D) that originally isolated from extracts of 
the marine sponge Halichondria okadai as a potential anti-cancer agent [46]. Okadaic acid was 
subsequently found to have cancerous tumor promoting activity in the two-stage model of 
carcinogenesis on mouse skin [47], which makes a limitation in its clinical use. Moreover, these 
seemingly paradoxical responses to okadaic acid exposure have subsequently led to the widespread 
recognition of the central roles that several classes of protein serine/threonine phosphatases, the 
primary cellular targets of okadaic acid, play in the regulation of many essential cellular processes, 
including metabolism, growth, division, and death [48]. Hence, okadaic acid has emerged as a key 
laboratory tool for identifying and studying the myriad of events associated with the inhibition of 
protein serine/threonine phosphatases [49; 50]. Okadaic acid is the first member of an entire class of 
remarkably distinct secondary metabolites from such disparate organisms as bacteria, blue-green algae, 
red algae, and even insects that together comprise the "okadaic acid class" of phosphatase inhibitors 
[51, 52]. 
Today, okadaic acid is being employed in basic studies directed towards understanding such diverse 
human disease related processes as cancer, AIDS, inflammation, osteoporosis, Alzheimer's, and 
diabetes [49; 50]. Phosphorylation level in cells results of a delicate balance between protein 
phosphatases and protein kinases. Kinases transfer a phosphate from ATP to a protein. Phosphatases 
remove the phosphate group from the substrate protein [50]. Regulation of the levels of 
phosphorylated proteins is fundamental to a large number of cellular processes. These include changes 
in gene expression, muscle contraction, protein synthesis, intracellular transport and cell cycle 
progression, apoptosis or glycogen metabolism. Breakdown of endogenous glycogen stores provided 
glucose, which is a fundamental source of energy for all eukaryotic cells. These energy stores are 
replenished from glucose in the diet [53]. Certain tissues such as gut, muscle and adipose tissue, have 
acquired a highly specialized glucose-transport systems. The activity of transporters can be rapidly Int. J. Mol. Sci. 2008, 9  
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upregulated to allow these tissues to increase their rate of glucose transport by 10–40-fold in minutes. 
Those systems are crucial during the absorptive period (after a meal), to facilitate the rapid insulin-
dependent storage of glucose in muscle and adipose tissue, so preventing large fluctuations in blood 
glucose levels. Dysfunctional glucose uptake into muscle and fat cells contributes to the onset of type 
II diabetes [53]. 
However, the application of okadaic acid is presently limited by several factors. Firstly, this 
compound is an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter, which was 
never considered as a treatment option [9]. Secondly, okadaic acid lacks sufficient specificity in its 
inhibition of okadaic acid-sensitive protein phosphatases. Hence, relatively indiscriminant phosphatase 
inhibition may simultaneously affect a variety of important cellular processes, in addition to the 
targeted ones. Finally, the current commercial sources of okadaic acid are primarily isolation in small 
quantities from cultured dinoflagellates, single celled marine microorganisms [54]. This provides 
research quantities at high costs, whereas the availability of specific inhibitors of the protein 
serine/threonine phosphatases remains to be developed. However, alternative sources of okadaic acid 
and, more importantly, structurally related compounds have been emerging in recent years via 
laboratory total synthesis [55]. Total synthesis offers unique opportunities to tailor the details of the 
okadaic acid architecture with the aim of developing an empirical understanding of the relationship 
between structure, function, and specificity [56]. Concurrently, structural information of the protein 
phosphatase targets of okadaic acid has been acquired, largely through X-ray crystallography [57]. The 
detailed topological and intermolecular recognition data of the okadaic acid receptors combines with 
the ability to generate specifically designed structural variants of okadaic acid to provide unique 
contemporary opportunities to develop specific regulators of essential cellular processes via the 
selective modulation of phosphatase activity. 
 
2.4. Rapamycin: an inhibitor of mTOR-dependent signaling pathways 
Rapamycin (Figure 1E) is a natural product with antimicrobial and immunosuppressant activities 
due to its ability to inhibit signal transduction cascades [58]. Rapamycin is a potent 
immunosuppressant that inhibits interleukin-2 (IL-2) signaling and prevents T-cell proliferation by 
inhibiting progression from G1 to S-phase of the cell-cycle. The fact that IL-2-deficient mice are not 
markedly immunocompromised, even though rapamycin is potently immunosuppressive, suggests that 
rapamycin probably blocks signaling by additional cytokines, possibly including interleukins 4, 7, 9 
and 13, all of whose receptors share the gamma-subunit of the IL-2 receptor. Rapamycin may therefore 
inhibit a downstream signaling component shared by these receptors. In both yeast and mammalian 
cells, the action of rapamycin is mediated by its association with a highly conserved binding protein, 
the peptidylprolyl isomerase FKBP12 [59]. Remarkably, yeast mutants lacking FKBP12 are viable and 
resistant to rapamycin toxicity, indicating that both the protein and the drug are required for rapamycin 
action and providing strong support for a model in which the FKBP12-rapamycin complex is the 
active  in vivo agent. Overexpression of FKBP12 in mammalian cells increases sensitivity to 
rapamycin, and cell lines with reduced levels of FKBP12 are rapamycin resistant, providing evidence 
that FKBP12 is the conserved target of rapamycin action in yeast and mammals [60].   Int. J. Mol. Sci. 2008, 9  
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The targets of the toxic FKBP12-rapamycin complex are novel kinase homologs, the  target-of-
rapamycin kinase 1 (TOR1) and TOR2 proteins in yeast and mTOR protein in mammals, which are 
conserved from yeast to humans. Genetic studies in yeast, in which rapamycin-resistant mutants were 
isolated, first implicated the TOR1 and TOR2 gene products as targets of the FKBP12-rapamycin 
complex [61]. Analysis of the cloned TOR1 and TOR2 genes revealed the potential to encode large (~ 
280-kDa) proteins that have 67% overall identity [62]. However, despite this remarkable similarity, 
TOR1 and TOR2 serve both shared and distinct functions. Deletion of the TOR1 gene confers only a 
modest growth defect under most conditions, whereas deletion of TOR2 is lethal. Subsequently, a 
mammalian TOR homolog (mTOR/ FRAP/ RAFT1/ SEP/ RAPT1) was identified by its ability to 
physically interact with FKBP12-rapamycin and was found to have ~50% identity to the yeast TOR 
proteins [63]. The highest level of identity between the yeast and the mammalian TOR proteins is in 
the carboxyl-terminal domain, which exhibits sequence identity to both lipid and protein kinases. The 
X-ray structure of FKBP12-rapamycin bound to a small portion of the mTOR protein (the FRB 
domain) has been solved [64]. This structure revealed that rapamycin docks into a hydrophobic pocket 
on the surface of the TOR protein that has been highly conserved from yeast to humans. Few protein-
protein contacts are apparent in the X-ray structure, but they should exist and play an important role in 
the complex, because rapamycin does not bind to the mTOR protein alone and thus FKBP12-TOR 
contacts should contribute to the ternary complex. Genetic studies had identified three residues that 
play a critical role in FKBP12-rapamycin binding to the yeast TOR1 and TOR2 proteins [65]; these 
three residues, Ser1975, Trp2042, and Phe2049, are all conserved in the mammalian TOR protein and 
form the base and sides of the hydrophobic rapamycin binding pocket on mTOR [66]. 
It has been a question that what are the substrates of mTOR and which of them are involved in cell-
cycle control and translational regulation. Several studies have demonstrated that rapamycin inhibits 
the activation of p70S6K, but this kinase does not appear to be a direct target for rapamycin. The S6 
protein is a component of the 40S ribosomal subunit and, as phosphorylation of the S6 protein by 
p70S6K correlates with increased translation, this suggests one possible mechanism by which 
rapamycin could inhibit translation. On the other hand, p70S6K has also been linked to transcriptional 
control by the cAMP-responsive element modulator, suggesting a role in transcriptional regulation 
[67]. It is worth noting that the effects of rapamycin on yeast and mammalian cells are remarkably 
similar, but no yeast homologue of p70S6K is apparent in the now-completed sequence of the yeast 
genome. Another downstream target of mTOR is the eukaryotic translation-initiation factor 4E (eIF-
4E)-binding protein PHAS-I, which plays a key role in regulating translational initiation. PHAS-I 
binds to and inhibits the function of eIF-4e, which normally recognizes the 7-methylguanine cap on 
mRNA to initiate translation. PHAS-I is phosphorylated and inactivated in response to growth-factor 
stimulation, releasing eIF-4e to activate translation. Rapamycin blocks the phosphorylation of PHAS-I 
in vivo and inhibits mTOR-dependent phosphorylation of recombinant PHAS-I in vitro [68]. Recent 
findings suggest that the two proteins known to function downstream of mammalian mTOR (p70S6K 
and PHAS-I) may represent two distinct signaling pathways, because the phosphorylation of PHAS-I 
by mTOR is still rapamycin sensitive in cells expressing a rapamycin-resistant form of p70S6K [69]. 
The cyclin-dependent-kinase (CDK) inhibitor p27kip1 also plays a role in rapamycin-dependent cell 
cycle arrest in mammalian cells. p27kip1 is degraded following stimulation of T cells with IL-2, and 
rapamycin treatment prevents p27kip1 degradation [70]. In addition, cell lines that are partially Int. J. Mol. Sci. 2008, 9  
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resistant to rapamycin express very low levels of p27kip1, and cells derived from p27-knockout mice 
are also partially rapamycin resistant [71]. The regulation of p27kip1 may therefore represent a 
rapamycin-sensitive step in pathways regulating cell-cycle progression and arrest in T cells. 
 
3. Conclusions 
These five natural products have significantly contributed the understanding of molecular 
mechanisms of action in PI3K/PDK1/PKB pathways activated by insulin and other growth factors. 
Toxins that originally evolved to kill competing microorganisms can be used as quite specific agents in 
complex animals, although these are known to be toxic in our body. In particular, toxin compounds 
mentioned in this review are reported to be cancer promoter or toxic in cellular or organic systems and 
mainly known as a blocker of insulin effects. Due to this, these toxins can never be used to human for 
curing insulin-mediated diseases such as diabetes. Nonetheless, these compounds greatly helped in 
exploring molecular activation mechanisms on the functional activation of PI3K, PDK1 and PKB, as 
well as their substrate proteins upon insulin treatment. These finding also rendered us to develop novel 
drugs to treat insulin-dependent diabetes and other metabolic diseases. These aspects indicate that most 
of natural products including toxins can be considered as a valuable source to investigate cellular 
events, regardless of their toxicological profiles. Therefore, it is expected that additional biochemical 
events will be further understood by another natural inhibitors derived from microorganisms and plants 
and will give us an opportunity to realize more complicate biological processes. 
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